Summit Therapeutics plc Summit Therapeutics Plc : Holding(s) In Company

 
TIDMSUMM 
 
 
 
 
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) 
 
1. Identity of the issuer or the underlying issuer                 SUMMIT THERAPEUTICS PLC 
 of existing shares to which voting rights are 
 attached: (ii) 
2 Reason for the notification (please tick the appropriate 
 box or boxes): 
An acquisition or disposal of voting rights                                   x 
An acquisition or disposal of qualifying financial 
 instruments which may result in the acquisition of 
 shares already issued to which voting rights are attached 
An acquisition or disposal of instruments with similar 
 economic effect to qualifying financial instruments 
An event changing the breakdown of voting rights 
Other (please specify): 
3. Full name of person(s) subject to the                                      ROBERT KEITH 
 notification obligation: (iii) 
4. Full name of shareholder(s) 
 (if different from 3.):(iv) 
5. Date of the transaction and date on                                     20 JANUARY 2017 
 which the threshold is crossed or 
 reached: (v) 
6. Date on which issuer notified:                                          25 JANUARY 2017 
7. Threshold(s) that is/are crossed or                                        BELOW 8%, 7% 
 reached: (vi, vii) 
 
 
 
 
8. Notified details: 
A: Voting rights attached to shares (viii, ix) 
Class/type of 
 shares                     Situation previous 
 if possible using           to the triggering 
 the ISIN CODE               transaction                        Resulting situation after the triggering transaction 
                                              Number 
                            Number             of 
                             of                Voting           Number                        Number of voting 
                             Shares            Rights            of shares                     rights                                           % of voting rights (x) 
                                                                Direct                        Direct (xi)           Indirect (xii)              Direct             Indirect 
GB00B8DX2616                4,040,610         4,040,610         3,040,610                     3,040,610                                         4.9% 
 
 
B: Qualifying Financial Instruments 
Resulting situation after the triggering transaction 
                                                                                                Number of voting 
                                                                                                 rights that may be 
                                                                                                 acquired if the 
Type of financial               Expiration      Exercise/                                        instrument is                                      % of voting 
 instrument                      date (xiii)     Conversion Period (xiv)                         exercised/ converted.                               rights 
AMERICAN DEPOSITORY SHARES 
 (ADS)                          N/A             N/A                                             1,164,700                                           1.88% 
 
C: Financial Instruments with similar economic effect 
 to Qualifying Financial Instruments (xv, xvi) 
Resulting situation after the triggering transaction 
Type of financial                             Expiration      Exercise/ Conversion 
 instrument                   Exercise price  date (xvii)     period (xviii)                  Number of voting rights instrument refers to        % of voting rights (xix, xx) 
 
Spreadbet                                                                                      89,506                                             Nominal            Delta 
                                                                                                                                                  .14% 
 
Total (A+B+C) 
Number of voting rights                                           Percentage of voting rights 
4,294,816                                                         6.92% 
 
 
 
 
9. Chain of controlled undertakings through which 
 the voting rights and/or the 
 financial instruments are effectively held, if applicable: 
 (xxi) 
 
 
Proxy Voting: 
10. Name of the proxy holder: 
11. Number of voting rights proxy holder will cease 
 to hold: 
12. Date on which proxy holder will cease to hold 
 voting rights: 
 
 
 13. Additional information: 
14. Contact name:                                         JOCELYN M. BENNETT 
15. Contact telephone number:                                [phone] 
 
 
 
   This announcement is distributed by Nasdaq Corporate Solutions on behalf 
of Nasdaq Corporate Solutions clients. 
 
   The issuer of this announcement warrants that they are solely 
responsible for the content, accuracy and originality of the information 
contained therein. 
 
   Source: Summit Therapeutics plc via Globenewswire 
 
 
  http://www.summitplc.com/ 
 

(END) Dow Jones Newswires

January 25, 2017 07:45 ET (12:45 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.